Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer

Fabrice Andre, Maria V. Dieci, Peter Dubsky, Christos Sotiriou, Giuseppe Curigliano, Carsten Denkert, Sherene Loi

Research output: Contribution to journalArticle

Abstract

The immune system could mediate the antitumor activity of several anticancer treatments. Several chemotherapy compounds, including anthracyclines and oxaliplatin, induce immunogenic cell death that in turn activates antitumor immune response. Trastuzumab induces antibody-dependant cell-mediated cytotoxicity. On the basis of this background, immune markers have recently been the focus of intense translational research to predict and monitor the efficacy of treatments. Gene expression arrays andimmunohistochemistry have assessed immune activation and infiltration by macrophages, natural killer, and T and B lymphocytes. Using these approaches, several retrospective analyses of large trials have shown that activation of immune pathway may predict treatment efficacy and outcome in patients with breast cancers. As examples, intratumoral infiltration by lymphocytes and interferon-response in primary tumor predicted the efficacy of neoadjuvant chemotherapy. Intratumoral infiltration by lymphocytes was associated with good prognosis in patients with triple-negative breast cancer treated with adjuvant chemotherapy. More recently, it has been suggested that lymphocyte infiltration could also predict efficacy of trastuzumab. Finally, small retrospective studies have suggested that postchemotherapy lymphocyte infiltrates could be associated with better outcome in patients who did not reach pathologic complete response. This body of evidence suggests that assessing immune infiltration and activation could be useful in the future to stratify breast cancer patients. In addition, they provide evidence for the development of immunotherapies in breast cancer patients.

Original languageEnglish
Pages (from-to)28-33
Number of pages6
JournalClinical Cancer Research
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

Breast Neoplasms
Lymphocytes
oxaliplatin
Triple Negative Breast Neoplasms
Therapeutics
Drug Therapy
Translational Medical Research
Macrophage Activation
Anthracyclines
Adjuvant Chemotherapy
Immunotherapy
Interferons
Immune System
B-Lymphocytes
Cell Death
Retrospective Studies
Biomarkers
T-Lymphocytes
Gene Expression
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Molecular pathways : involvement of immune pathways in the therapeutic response and outcome in breast cancer. / Andre, Fabrice; Dieci, Maria V.; Dubsky, Peter; Sotiriou, Christos; Curigliano, Giuseppe; Denkert, Carsten; Loi, Sherene.

In: Clinical Cancer Research, Vol. 19, No. 1, 01.01.2013, p. 28-33.

Research output: Contribution to journalArticle

Andre, Fabrice ; Dieci, Maria V. ; Dubsky, Peter ; Sotiriou, Christos ; Curigliano, Giuseppe ; Denkert, Carsten ; Loi, Sherene. / Molecular pathways : involvement of immune pathways in the therapeutic response and outcome in breast cancer. In: Clinical Cancer Research. 2013 ; Vol. 19, No. 1. pp. 28-33.
@article{dc3f19b5b6184e5aa0b71be35d7e802e,
title = "Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer",
abstract = "The immune system could mediate the antitumor activity of several anticancer treatments. Several chemotherapy compounds, including anthracyclines and oxaliplatin, induce immunogenic cell death that in turn activates antitumor immune response. Trastuzumab induces antibody-dependant cell-mediated cytotoxicity. On the basis of this background, immune markers have recently been the focus of intense translational research to predict and monitor the efficacy of treatments. Gene expression arrays andimmunohistochemistry have assessed immune activation and infiltration by macrophages, natural killer, and T and B lymphocytes. Using these approaches, several retrospective analyses of large trials have shown that activation of immune pathway may predict treatment efficacy and outcome in patients with breast cancers. As examples, intratumoral infiltration by lymphocytes and interferon-response in primary tumor predicted the efficacy of neoadjuvant chemotherapy. Intratumoral infiltration by lymphocytes was associated with good prognosis in patients with triple-negative breast cancer treated with adjuvant chemotherapy. More recently, it has been suggested that lymphocyte infiltration could also predict efficacy of trastuzumab. Finally, small retrospective studies have suggested that postchemotherapy lymphocyte infiltrates could be associated with better outcome in patients who did not reach pathologic complete response. This body of evidence suggests that assessing immune infiltration and activation could be useful in the future to stratify breast cancer patients. In addition, they provide evidence for the development of immunotherapies in breast cancer patients.",
author = "Fabrice Andre and Dieci, {Maria V.} and Peter Dubsky and Christos Sotiriou and Giuseppe Curigliano and Carsten Denkert and Sherene Loi",
year = "2013",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-11-2701",
language = "English",
volume = "19",
pages = "28--33",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Molecular pathways

T2 - involvement of immune pathways in the therapeutic response and outcome in breast cancer

AU - Andre, Fabrice

AU - Dieci, Maria V.

AU - Dubsky, Peter

AU - Sotiriou, Christos

AU - Curigliano, Giuseppe

AU - Denkert, Carsten

AU - Loi, Sherene

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The immune system could mediate the antitumor activity of several anticancer treatments. Several chemotherapy compounds, including anthracyclines and oxaliplatin, induce immunogenic cell death that in turn activates antitumor immune response. Trastuzumab induces antibody-dependant cell-mediated cytotoxicity. On the basis of this background, immune markers have recently been the focus of intense translational research to predict and monitor the efficacy of treatments. Gene expression arrays andimmunohistochemistry have assessed immune activation and infiltration by macrophages, natural killer, and T and B lymphocytes. Using these approaches, several retrospective analyses of large trials have shown that activation of immune pathway may predict treatment efficacy and outcome in patients with breast cancers. As examples, intratumoral infiltration by lymphocytes and interferon-response in primary tumor predicted the efficacy of neoadjuvant chemotherapy. Intratumoral infiltration by lymphocytes was associated with good prognosis in patients with triple-negative breast cancer treated with adjuvant chemotherapy. More recently, it has been suggested that lymphocyte infiltration could also predict efficacy of trastuzumab. Finally, small retrospective studies have suggested that postchemotherapy lymphocyte infiltrates could be associated with better outcome in patients who did not reach pathologic complete response. This body of evidence suggests that assessing immune infiltration and activation could be useful in the future to stratify breast cancer patients. In addition, they provide evidence for the development of immunotherapies in breast cancer patients.

AB - The immune system could mediate the antitumor activity of several anticancer treatments. Several chemotherapy compounds, including anthracyclines and oxaliplatin, induce immunogenic cell death that in turn activates antitumor immune response. Trastuzumab induces antibody-dependant cell-mediated cytotoxicity. On the basis of this background, immune markers have recently been the focus of intense translational research to predict and monitor the efficacy of treatments. Gene expression arrays andimmunohistochemistry have assessed immune activation and infiltration by macrophages, natural killer, and T and B lymphocytes. Using these approaches, several retrospective analyses of large trials have shown that activation of immune pathway may predict treatment efficacy and outcome in patients with breast cancers. As examples, intratumoral infiltration by lymphocytes and interferon-response in primary tumor predicted the efficacy of neoadjuvant chemotherapy. Intratumoral infiltration by lymphocytes was associated with good prognosis in patients with triple-negative breast cancer treated with adjuvant chemotherapy. More recently, it has been suggested that lymphocyte infiltration could also predict efficacy of trastuzumab. Finally, small retrospective studies have suggested that postchemotherapy lymphocyte infiltrates could be associated with better outcome in patients who did not reach pathologic complete response. This body of evidence suggests that assessing immune infiltration and activation could be useful in the future to stratify breast cancer patients. In addition, they provide evidence for the development of immunotherapies in breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84871949633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871949633&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-2701

DO - 10.1158/1078-0432.CCR-11-2701

M3 - Article

C2 - 23258741

AN - SCOPUS:84871949633

VL - 19

SP - 28

EP - 33

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -